From new leadership to product launches, here are five key updates from spine and orthopedic devicemakers since Jan. 15.

Johnson & Johnson’s stock dropped more than 3% Wednesday after the medical-technology and drug company beat estimates for the fourth quarter but as lower sales guidance for the year stoked fears of ...

Intra-Cellular Therapies makes Caplyta, a once-daily pill for adults with schizophrenia and bipolar-related depression ...

Following the report, several state legislators – including Carr, K.C. Ohaebosim, Henry Helgerson, Susan Estes, Angela ...

whole-body ultrasound today announced preliminary findings from a seminal study conducted by Rutgers Robert Wood Johnson Medical School (RWJMS) and Robert Wood Johnson University Hospital (RWJUH ...

The deal would help accelerate growth in J&J's drugs business after the company spun off its consumer health unit in 2023.

More powerful winds were expected to trigger new wildfires that could set back the recent progress made in containing blazes that have destroyed thousands of homes and killed at least 24 people ...

Johnson & Johnson reported higher-than-expected fourth-quarter revenues, driven by strong cancer drug sales, amidst its ...

Other medical experts interviewed questioned ... evidence for health and for establishing a clean food supply chain," Johnson says. "And so we're hoping to bridge these things to the new ...

More powerful winds were expected to trigger new wildfires that could set back the recent progress made in containing blazes ...

The wind chill reached minus 27 and a fan nearly lost his fingers on a frigid night a year ago in Kansas City.

Johnson & Johnson provides healthcare products across three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care ...